期刊
EUROPEAN JOURNAL OF CANCER
卷 153, 期 -, 页码 16-26出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2021.04.039
关键词
BRAF-mutant; Metastatic colorectal cancer; FOLFOXIRI/bevacizumab; BM1/BM2 subtypes; LI/LD-Wnt pathway
类别
资金
- ARCO Foundation
- University of Pisa
- Regione Toscana (Bando Ricerca Salute 2018 IN BILICO project)
The TRIBE2 study did not find specific gene expression signatures that could identify BRAF-mutant mCRC patients who may benefit more from upfront FOLFOXIRI/bevacizumab. However, it did show that patients with ECOG-PS >0 and left-sided tumors may not benefit from intensified treatment.
Background: Recent data from the TRIBE2 study have failed to suggest a higher magnitude of benefit from upfront FOLFOXIRI/bevacizumab in patients with BRAF-mutant metastatic colorectal cancer (mCRC) as previously reported in the TRIBE study. Patients and methods: Clinical characteristics and gene expression signatures of patients with BRAF-mutant mCRC enrolled in the TRIBE2 study were evaluated with the aim of understanding that patients may derive benefit from the intensification of the upfront chemotherapy. Results: Of 46 BRAF-mutant tumour samples analysed, 24 (52%) and 22 (48%) were classified as BM1 and BM2, respectively, and 27 (59%) and 19 (41%) were assigned to ligand-independent (LI) and ligand-dependent (LD) Wnt pathway subgroups, respectively. No prognostic impact was shown for both BM1/BM2 and LI/LD subtypes. No interaction was evident between BM1/BM2 or LI/LD signatures and the benefit provided by FOLFOXIRI/bevacizumab. Significant interaction effect was evident in terms of progression-free survival between treatment arm and primary tumour sidedness (P = 0.05) and Eastern Cooperative Oncology Group performance status (ECOG-PS; P < 0.001). Conclusions: Gene expression analysis failed to identify patients with BRAF-mutant mCRC candidate to upfront FOLFOXIRI/bevacizumab. ECOG-PS >0 and left-sidedness seem associated with no benefit from the intensified treatment. (C) 2021 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据